Intraocular lymphoma: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 55: | Line 55: | ||
==Risk Factors== | ==Risk Factors== | ||
*Common risk factors in the development of intraocular lymphoma | *Common risk factors in the development of intraocular lymphoma, include: | ||
== Natural History, Complications and Prognosis== | == Natural History, Complications and Prognosis== | ||
*The majority of patients with intraocular lymphoma remain asymptomatic for [duration/years]. | *The majority of patients with intraocular lymphoma remain asymptomatic for [duration/years]. |
Revision as of 19:19, 9 May 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3
Overview
Historical Perspective
- Intraocular lymphoma was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
Classification
- Intraocular lymphoma may be classified according to [classification method] into [number] subtypes/groups:
- [group1]
- [group2]
- [group3]
Pathophysiology
- The pathogenesis of intraocular lymphoma is characterized by
- Genes associated with the development of intraocular lymphoma, include:
- On gross pathology, characteristic findings of intraocular lymphoma, include:
- On microscopic histopathological analysis, characteristic findings of intraocular lymphoma, include:
Causes
- Common causes of intraocular lymphoma, include:
Differentiating Intraocular Lymphoma from Other Diseases
- Intraocular lymphoma must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
- [Differential dx1]
- [Differential dx2]
- [Differential dx3]
Epidemiology and Demographics
- The prevalence of intraocular lymphoma is approximately [number or range] per 100,000 individuals worldwide.
- In [year], the incidence of intraocular lymphoma was estimated to be [number or range] cases per 100,000 individuals in [location].
Age
- Patients of all age groups may develop intraocular lymphoma.
- Intraocular lymphoma is more commonly observed among patients aged [age range] years old.
- Intraocular lymphoma is more commonly observed among [elderly patients/young patients/children].
Gender
- Intraocular lymphoma affects men and women equally.
- [Gender 1] are more commonly affected with intraocular lymphoma than [gender 2].
- The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
Race
- There is no racial predilection for intraocular lymphoma.
- Intraocular lymphoma usually affects individuals of the [race 1] race.
- [Race 2] individuals are less likely to develop intraocular lymphoma.
Risk Factors
- Common risk factors in the development of intraocular lymphoma, include:
Natural History, Complications and Prognosis
- The majority of patients with intraocular lymphoma remain asymptomatic for [duration/years].
- Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
- If left untreated, [#%] of patients with intraocular lymphoma may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
- Common complications of intraocular lymphoma include [complication 1], [complication 2], and [complication 3].
- Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with intraocular lymphoma is approximately [#%].
Diagnosis
Diagnostic Criteria
- The diagnosis of intraocular lymphoma is made when at least [number] of the following [number] diagnostic criteria are met:
- [criterion 1]
- [criterion 2]
- [criterion 3]
- [criterion 4]
Symptoms
- Intraocular lymphoma is usually asymptomatic.
- Symptoms of intraocular lymphoma may include the following:
- [symptom 1]
- [symptom 2]
- [symptom 3]
- [symptom 4]
- [symptom 5]
- [symptom 6]
Physical Examination
- Patients with intraocular lymphoma usually appear [general appearance].
- Physical examination may be remarkable for:
- [finding 1]
- [finding 2]
- [finding 3]
- [finding 4]
- [finding 5]
- [finding 6]
Laboratory Findings
- There are no specific laboratory findings associated with intraocular lymphoma.
- A [positive/negative] [test name] is diagnostic of intraocular lymphoma.
- An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of intraocular lymphoma.
- Other laboratory findings consistent with the diagnosis of intraocular lymphoma include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
Imaging Findings
- There are no [imaging study] findings associated with intraocular lymphoma.
- [Imaging study 1] is the imaging modality of choice for intraocular lymphoma.
- On [imaging study 1], intraocular lymphoma is characterized by [finding 1], [finding 2], and [finding 3].
- [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
Other Diagnostic Studies
- Intraocular lymphoma may also be diagnosed using [diagnostic study name].
- Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
Treatment
Medical Therapy
- There is no treatment for intraocular lymphoma; the mainstay of therapy is supportive care.
- The mainstay of therapy for intraocular lymphoma is [medical therapy 1] and [medical therapy 2].
- [Medical therapy 1] acts by [mechanism of action1].
- Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
Surgery
- Surgery is the mainstay of therapy for intraocular lymphoma.
- [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of intraocular lymphoma.
- [Surgical procedure] can only be performed for patients with [disease stage] intraocular lymphoma.
Prevention
- There are no primary preventive measures available for intraocular lymphoma.
- Effective measures for the primary prevention of intraocular lymphoma include [measure1], [measure2], and [measure3].
- Once diagnosed and successfully treated, patients with intraocular lymphoma are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].